ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,304.72
      0.70%
      US Tech 100
      18,318.00
      0.95%
      Dow Jones
      39,069.59
      0.01%
      Brent Oil
      81.965
      0.00%
      Bitcoin
      68,920.65
      0.57%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Centessa Pharmaceuticals PLC (CNTA)

      7. Centessa Pharmaceuticals PLC (CNTA) News

      CNTA

      Centessa Pharmaceuticals (CNTA)

      Centessa Pharmaceuticals PLC
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:CNTA
      DateTimeSourceHeadlineSymbolCompany
      05/21/20248:45AMGlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
      05/13/20244:32PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTACentessa Pharmaceuticals PLC
      05/13/20244:23PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
      05/13/20244:10PMGlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
      05/09/20248:01AMEdgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:CNTACentessa Pharmaceuticals PLC
      05/09/20248:00AMEdgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNTACentessa Pharmaceuticals PLC
      04/23/20249:36PMGlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
      04/23/20244:17PMGlobeNewswire Inc.Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
      04/22/20247:00AMGlobeNewswire Inc.Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024NASDAQ:CNTACentessa Pharmaceuticals PLC
      03/28/20244:28PMGlobeNewswire Inc.Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023NASDAQ:CNTACentessa Pharmaceuticals PLC
      02/22/20248:00AMGlobeNewswire Inc.Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/09/20247:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/09/20247:00AMGlobeNewswire Inc.Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia andNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/02/20245:10PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/02/20245:09PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/02/20245:07PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/02/20245:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/02/20245:03PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      02/01/20244:07PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      01/22/20248:00AMGlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
      01/09/20247:56AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
      01/02/20247:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      01/02/20247:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      01/02/20247:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      01/02/20247:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      01/02/20247:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
      12/13/20238:00AMGlobeNewswire Inc.Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare ConferenceNASDAQ:CNTACentessa Pharmaceuticals PLC
      12/11/20237:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
      12/10/202312:05PMGlobeNewswire Inc.Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of HemophiliaNASDAQ:CNTACentessa Pharmaceuticals PLC
      11/27/20234:15PMGlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:CNTACentessa Pharmaceuticals PLC
       Showing the most relevant articles for your search:NASDAQ:CNTA